NOW APPROVED FOR INTERMEDIATE RISK PATIENTS

Man leaning on bumper of car, petting dog, looking at horizon
Device

EVOLUT™ TAVR

PLATFORM

Provides benefits that intermediate risk patients need — unsurpassed hemodynamics, reliable performance and an excellent safety profile.

COREVALVE™ AND

EVOLUT™ R TAVR

SYSTEMS

SURTAVI CLINICAL

TRIAL RESULTS

A Groundbreaking Study of Intermediate Risk Symptomatic Severe Aortic Stenosis Patients

Play Video Michael J. Reardon

Michael J. Reardon, M.D., Methodist DeBakey Heart & Vascular Center Houston TX

BUILT ON A PROVEN PLATFORM

DESIGNED FOR DURABILITY

SEE PROOF

UNSURPASSED HEMODYNAMICS

SEE PROOF

OUTCOMES THAT MATTER

SEE PROOF

LOW RATES OF DISABLING STROKE

SEE PROOF
 
CoreValve ADVANCE Study 5-Year Results

DESIGNED FOR

DURABILITY

Clinical data from the legacy CoreValve platform, demonstrating sustained valve performance out to five years1

 
Faster Functional Recovery, Shorter Hospital Stays Graph

OUTCOMES

THAT MATTER

Shorter hospital stays and faster functional recovery times for patients treated with TAVR vs. SAVR.

 
TAVR had significantly better valve performance over SAVR at all follow-up visits

UNSURPASSED HEMODYNAMICS

Supra-annular valve design maximizes leaflet coaptation and promotes single-digit gradients and large EOAs

Device
 
Bayesian Analysis: 24-Month Disabling Stroke

LOW RATES OF DISABLING STROKE

Excellent early outcomes at 30 days that persist out through 24 months

1.2% 30-Day Disabling Stroke Rate for TAVR ARM

All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic.
*Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.


1

Barbanti, et al., J Am Coll Cardiol Intv 2015; 8: 1084-91.